Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure accepted as late-breaker oral presentation on May 21 at 10:30 am ET –


– Findings from the STARS...

Related Keywords

Washington ,United States ,Boston ,Massachusetts ,China ,Japan ,Switzerland ,Michael Shetzline ,Ironwood Pharmaceuticals Nasdaq ,Linkedin ,Exchange Commission ,Astrazeneca ,A National Survey Analysis ,Ironwood Pharmaceuticals ,Ironwood Pharmaceuticals Inc ,Center Trial ,Nasdaq ,Drug Administration ,Disease Week ,Apraglutide Once Weekly ,Short Bowel Syndrome ,Intestinal Failure ,Global Phase ,Placebo Controlled Trial ,Bowel Morphology ,Motility Assessed ,Short Bowel Syndrome Intestinal Failure ,Colon In Continuity Treated ,Support Weaning ,Clinical Benefit ,Improved Patient Reported Outcomes ,Long Acting Glucagon Like ,Analog Apraglutide ,Increased Oral Intake ,Improved Energy ,Carbohydrate Absorption ,Gastric Emptying ,Healthy Individuals ,Single Center Trial ,Bowel Syndrome ,Functional Constipation ,World Prescribing Patterns ,Pediatric Patients ,Irritable Bowel Syndrome ,National Survey Analysis ,Acute Graft Versus Host Disease ,Common Adverse Reactions ,Prescribing Information ,Boxed Warning ,Annual Report ,Markets ,